Back to search

University of British Columbia

The effect of angiotensin receptor blockers on cancer associated fibroblasts as a potential cancer therapy adjuvant

Abstract

dc:description

The tumour microenvironment (TME) harbours conditions that render current cancer therapies less effective. High levels of fibrosis from stromal cells can encourage poor vascular construction and can increase interstitial fluid pressure (IFP) in the tumour, both of which can negatively affect vascular perfusion. Impaired vascular perfusion can limit drug distribution throughout the tumour. Further, areas near faulty vasculature can become low in oxygen, or hypoxic, which directly inhibits radiation therapy efficacy. Fibrosis can also cause tumoural stiffness, which is correlated with worse patient response to treatment and worse survival. Possible adjuvant cancer therapies that aim to target fibrosis may also improve vascular perfusion and decrease tumoural stiffness, which could enhance the efficacy of existing cancer treatments. Angiotensin receptor blockers (ARBs), are a widely prescribed and well-tolerated group of antihypertensives, which have been reported to also have antifibrotic effects in liver, kidney, and heart diseases. In my work, I study the use of ARBs, as a putative antifibrotic to ameliorate cancer therapy efficacy. I first assess the use of ARBs and other antihypertensives within a retrospective study of patients with head and neck cancer. In this study, I hypothesize that the use of antihypertensives medications is correlated with improved patient survival (Chapter 2). Subsequently, I evaluate how one ARB, telmisartan, effects cancer associated fibroblasts (CAFs). In an in vivo tumour model, I study global transcriptional changes by employing the use of single-cell RNA-sequencing (scRNA-seq) on telmisartan-treated and control tumours from mouse xenografts (Chapter 3). Moreover, I extracted primary naïve dermal fibroblasts from mice and polarized them to specific states to study the effects of telmisartan on distinct fibroblast states ex vivo, analogous to CAF subtypes in the tumour (Chapter 4). Overall, my work shows that ARB use is correlated with improved head and neck cancer patient survival outcomes. Furthermore, I show that specific myofibroblast fibroblasts and myCAFs are responsive to telmisartan in both tumours and in ex vivo cells.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy - PhD
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Interdisciplinary Oncology
Grantor dc:publisher
University of British Columbia
Year dc:date
2025

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Lee, Che-Min
Contributors dc:contributor
  • Bennewith, Kevin L.

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/93380

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Lee, Che-Min. The effect of angiotensin receptor blockers on cancer associated fibroblasts as a potential cancer therapy adjuvant. doctoral thesis, University of British Columbia, 2025. http://hdl.handle.net/2429/93380